Red light therapy:
here is what the science actually says.

Red light therapy has a credibility problem. Not because the science is weak, it is not. The problem is that a decade of wellness marketing has buried the actual research under a mountain of before-and-after photos and breathless claims. When everything from wrinkle creams to phone cases carries the "red light" label, it becomes nearly impossible to separate what is scientifically validated from what is simply a glowing LED with a price tag.

So let us start from scratch. Let us talk about what photobiomodulation actually is, what it does at a cellular level, which wavelengths matter and why, and what you can realistically expect from a properly designed protocol used consistently over time.

Because here is the thing: the science genuinely is good. Hundreds of randomised controlled trials. Peer-reviewed publications in respected journals. Clinical use in dermatology, sports medicine, wound care, and neurology. Red light therapy is not alternative medicine. It is just surrounded by a lot of nonsense that has nothing to do with it.

What photobiomodulation actually is

Photobiomodulation (PBM) is the application of specific wavelengths of light to biological tissue to produce a therapeutic effect. The key word is "specific." Not all light is photobiomodulation. Not all red light is therapeutic. The mechanism is well understood at this point, and it comes down to one primary target: cytochrome c oxidase.

Cytochrome c oxidase is an enzyme in your mitochondria, the energy-producing organelles in your cells. It is part of the electron transport chain, the process by which your cells convert nutrients into ATP, the chemical currency of energy. Cytochrome c oxidase has a specific absorption spectrum: it preferentially absorbs certain wavelengths of light in the red and near-infrared range.

When those wavelengths penetrate skin and reach the mitochondria, cytochrome c oxidase absorbs the photons. This triggers a cascade of downstream effects: increased ATP production, reduced oxidative stress, upregulation of antioxidant pathways, and modulation of inflammatory signalling. Essentially, cells that are under metabolic stress, whether from age, UV damage, inflammation, or injury, begin functioning more efficiently.

This is not a placebo effect. It is a measurable, reproducible, dose-dependent biological response. The mechanism has been replicated across hundreds of independent studies.

The wavelengths that matter, and why everything else is largely marketing

This is where most of the confusion lives, and where most products fail. The therapeutic window for photobiomodulation is not "red light." It is a specific range of wavelengths, and the distinction matters enormously.

There are two primary therapeutic ranges, each with a different depth of tissue penetration and a different primary application.

Red light: 630-660nm. This range penetrates to roughly 1-5mm depth, making it highly effective for the dermis (the layer below the skin surface where fibroblasts live and collagen is produced). This is the range with the strongest evidence for skin texture improvement, collagen stimulation, wound healing, and surface inflammation reduction. It is also the range visible to the naked eye as red light.

Near-infrared: 810-850nm. This range is invisible to the naked eye and penetrates significantly deeper, reaching 5-10mm or more depending on tissue density. At this depth, it affects muscle tissue, deeper skin layers, joint structures, and in some research contexts, even neural tissue. The evidence here covers muscle recovery, joint inflammation, and pain reduction.

Wavelengths outside these ranges have dramatically weaker absorption by cytochrome c oxidase. A device emitting at 700nm or 900nm is not providing photobiomodulation. It is providing coloured light. This matters when evaluating any product claiming "red light therapy" benefits without specifying wavelengths. If the exact nanometre range is not disclosed, that is a significant red flag.

What the research actually shows

Let us get into the evidence, because this is where it gets genuinely interesting. I want to focus on the areas with the strongest research base, particularly those most relevant to women.

Collagen stimulation and skin quality

This is the most robustly studied application of photobiomodulation at the consumer level. Multiple randomised controlled trials, including a widely cited 2014 study published in Photomedicine and Laser Surgery, demonstrated significant improvements in skin complexion, skin feeling, and collagen density after consistent red light treatment. The mechanism is well understood: fibroblasts in the dermis, stimulated by 630-660nm light, upregulate collagen synthesis and reduce matrix metalloproteinase activity (the enzymes that break down collagen).

The results are not instant. Statistically significant improvements in controlled trials typically appear at 8-12 weeks of consistent use. The effect is real, but it requires patience and consistency that most people underestimate.

Reduction in inflammatory markers

PBM has demonstrated consistent effects on inflammatory cytokine profiles in multiple contexts. Studies show reduction in TNF-alpha, IL-6, and other pro-inflammatory markers following treatment. For women, where chronic low-grade inflammation underpins everything from skin ageing to joint pain to cardiovascular risk, this is a meaningful systemic benefit that extends well beyond cosmetic outcomes.

Wound healing and tissue repair

The wound healing application has some of the oldest evidence in the PBM literature, dating to early laser therapy research in the 1960s and 70s. LED-based PBM at therapeutic wavelengths consistently demonstrates accelerated wound closure, reduced scar formation, and improved tissue quality in both clinical and controlled research settings.

What red light therapy will not do

Honesty matters here, and this is where I diverge from most red light marketing. There are real limitations, and knowing them protects your time, money, and expectations.

• It will not fix a poor diet. Collagen synthesis requires adequate protein and vitamin C. Inflammation management requires a diet that is not actively driving it. No amount of photobiomodulation overrides a consistently inflammatory lifestyle.
• It will not replace sunscreen. Red light supports collagen synthesis. UV exposure breaks it down. If you are using a face mask and then spending unprotected time in the South African sun, you are working against yourself.
• It will not deliver results in a single session. Anyone who shows you a single session before-and-after is showing you transient effects from increased circulation and mild tissue warming, not the photobiomodulation mechanism. Real results require weeks of consistent use.
• It will not work from an underpowered device. This is the most important limitation, and the one most consumers discover too late.

Why underpowered devices fail to deliver

Irradiance is the term that separates genuine photobiomodulation devices from decorative ones. Irradiance is the power of light delivered per unit area, measured in milliwatts per square centimetre (mW/cm2). The research literature on PBM uses specific irradiance levels: generally 20-200 mW/cm2 at the skin surface, depending on the application and tissue depth targeted.

Below a threshold irradiance, the photons simply do not have sufficient energy density to trigger the cytochrome c oxidase response. You get warmth. You get a pleasant glow. You do not get photobiomodulation.

Many devices on the market, particularly lower-priced LED masks, operate at irradiance levels well below this threshold. The LEDs emit light, the device looks impressive, and the marketing claims are identical to those of properly powered devices. The difference is invisible to the naked eye and only becomes apparent when you check the actual irradiance specifications. Most manufacturers of underpowered devices do not publish these specifications because the numbers would not support the claims.

LED density also matters significantly. A mask with 48 LEDs spread across the face cannot deliver the same even coverage as one with 488 LEDs across the same area. Lower density creates gaps in coverage, meaning portions of skin receive insufficient irradiance even if individual LEDs are adequately powered. The maths here is straightforward: more LEDs of the right wavelength at the right power equals more consistent therapeutic coverage.

Why women specifically benefit from photobiomodulation

The research on PBM is not sex-specific in most cases, but the application to female biology is particularly compelling in several areas that deserve attention.

Collagen loss in women is not a gradual, linear process. Oestrogen actively supports collagen synthesis throughout the reproductive years. When oestrogen declines at menopause, collagen loss accelerates dramatically: some research estimates women lose approximately 30% of skin collagen in the first five years post-menopause, with continued loss of 2% per year thereafter. This is not normal ageing. It is hormonally driven structural change, and it happens faster in women than in men of the same age.

Photobiomodulation at 630-660nm directly supports the fibroblast activity that maintains collagen density, working through a mechanism that does not require oestrogen. This means it can partially offset the accelerated collagen loss of perimenopause and post-menopause through a completely independent pathway. That is a meaningful and underappreciated benefit.

Beyond skin, inflammation is a central concern in women's health. Conditions with significant inflammatory components, including endometriosis, autoimmune conditions, joint pain, and the inflammatory changes that accompany perimenopause, are disproportionately represented in female populations. The anti-inflammatory effects of PBM, documented across multiple tissue types and delivered systemically through consistent use, are relevant to women in ways that extend well beyond aesthetics.

Recovery is another dimension. Near-infrared light at 850nm has documented effects on muscle recovery after exercise, reducing delayed onset muscle soreness and supporting faster return to training. For women who are trying to maintain or build muscle mass as they age (which, as we discussed in our body composition article, is critical for longevity), anything that improves recovery quality and consistency matters.

What a proper protocol looks like

Consistency is everything in photobiomodulation. The cellular changes that produce visible results are cumulative, and the research protocols that demonstrate significant outcomes are built around regular, sustained use.

Here is what the evidence supports for a face-focused skin protocol:

• Frequency: 4-5 sessions per week. Daily use is supported by the research and well-tolerated. Rest days are fine. Multiple sessions per day are not necessary and may produce diminishing returns at high doses.
• Session length: 10-20 minutes per session at appropriate irradiance levels. Longer is not always better. The dose-response curve for PBM is biphasic: too little has no effect, optimal dosing produces the therapeutic response, and very high doses can actually inhibit the same pathways. 10-20 minutes at 50-100 mW/cm2 sits in the well-documented therapeutic range.
• Skin preparation: clean skin with no barrier creams, SPF, or makeup. Light does not penetrate through occlusive products. Some studies suggest slightly moisturised skin may enhance penetration, but the primary requirement is no blockers.
• Timeline: expect no visible changes in the first 2-3 weeks. Measurable skin texture improvements typically appear from week 6-8. Collagen density changes in the dermis that are detectable by clinical assessment require 10-12 weeks minimum. This is not slow. It is what actual biological change looks like.
• Maintenance: the benefits of PBM are maintained with continued use but diminish if treatment is stopped. Think of it the same way you think of exercise: the results come from the habit, not the single session.

The science on red light therapy is genuinely solid. The problem has never been the research. The problem has been a market flooded with devices that lack the wavelength specificity or irradiance levels to do what the research actually demonstrates.

If you are going to invest time in a daily protocol, make sure what you are using can actually do the job.